First Patient Enrolled in Teleflex’s Barrigel™ Rectal Spacer Trial for Post Radical Prostatectomy Radiation Therapy (PPRT)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. IBM
10. HOOD

Go back to First Patient Enrolled in Teleflex’s Barrigel™ Rectal Spacer Trial for Post Radical Prostatectomy Radiation Therapy (PPRT)

Morgan Stanley Defending Teleflex (TFX), 'Stock Reaction Overdone'

October 31, 2024 4:04 PM EDT

Morgan Stanley analyst Patrick Wood reiterated an Overweight rating and $275.00 price target on Teleflex (NYSE: TFX).

The analyst comments "Stock Reaction Overdone: Although today's print was not a clean beat and raise, we don't think the stock deserves to be down 15%. In fact,... More